In partnership with Microsoft, Paige has introduced Virchow2 and Virchow2G, the latest generation of its AI foundation models for cancer. Built on an unprecedented dataset of 3 million pathology slides, these models represent a significant advancement in AI for clinical pathology.
Virchow2 and Virchow2G encompass a wide range of data, including over 40 tissue types and 225,000 patients from diverse backgrounds. This vast dataset provides a comprehensive view of cancer, ensuring the models can be applied to a broad spectrum of patients.
With an astonishing 1.8 billion parameters, Virchow2G is the largest pathology model ever created. These models, trained on Microsoft’s advanced supercomputing infrastructure, set a new benchmark in AI training scale, outperforming previous industry standards.
Virchow2 and Virchow2G have demonstrated superior performance in cancer detection. Paige has developed a universal clinical AI application leveraging these models to assist pathologists in identifying and diagnosing cancer across multiple tissue types. AI can significantly reduce the time and error associated with diagnosis, ensuring more accurate and timely patient care.
The scale and complexity of Virchow2 and Virchow2G unlock valuable information that can drive groundbreaking innovations in cancer research and treatment. These models enable precise diagnostics, targeted therapies, and personalized patient care.
Paige’s collaboration with Microsoft represents a pivotal milestone in developing Virchow, an AI tool that has garnered recognition in Nature Medicine. Virchow2 and Virchow2G exemplify the convergence of technology and science in the fight against cancer. By harnessing AI’s capabilities, we are moving closer to making precision medicine a reality for cancer patients worldwide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
